STOCK TITAN

CAN B CORP - $CANB STOCK NEWS

Welcome to our dedicated page for CAN B news (Ticker: $CANB), a resource for investors and traders seeking the latest updates and insights on CAN B stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CAN B's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CAN B's position in the market.

Rhea-AI Summary
Can B Corp. secures ownership of two cannabis patents valued at $122 million, potentially up to $750 million, extending to 2035. The patents cover cannabis extracts, liquid formulations, and methods of managing various conditions. Can B plans to monetize these patents in a growing industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary
Can B Corp. announces consolidation of Pure Health Product operations, saving nearly $500,000 annually. Colorado is now the base of operations for all manufacturing and shipping.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Can B Corp. has announced a newly awarded contract with One Bad Moon Rising and the purchase of 1.8 million pounds of biomass. The biomass is stored in Ft. Morgan, Colorado and is ready for immediate processing. The purchase price of the biomass was $2.7 million, paid with Rule 144 restricted stock. Can B's CEO is excited about the new opportunity and looks forward to utilizing their fully integrated operations to produce isomers. One Bad Moon Rising is impressed with Can B's facilities and is excited to fulfill the demand for isomers with their new contract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.43%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
CAN B CORP

OTC:CANB

CANB Rankings

CANB Stock Data

699.82k
24.09M
14.04%
0.96%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Hicksville

About CANB

canbiola, inc. (otcqb: canb) is a developer, manufacturer and seller of a variety of cannabidiol (hemp) based products such as oils, creams, moisturizers, chews,, isolate, gel caps, and concentrates. canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the cbd and the medical cannabis industry. cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure cbd products are legal in all 50 states. hemp cbd is the non-psychoactive component (no thc) used for treatment of pain, inflammation, and wellness programs. for more information about canbiola, inc., please visit: https://canbiola.com. additionally, canbiola’s wholly owned subsidiary pure health products, based in lacey, wa, is its prime development laboratory and production facility. canbiola’s duramed division has recently rolled out a durable medical device via its doctor network to treat pati